Department of Obstetrics and Gynecology, AOUI Verona, University of Verona, 37126 Verona, Italy.
Obstetrics and Gynecology Unit, Department of Woman, Child and General and Specialized Surgery, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy.
Medicina (Kaunas). 2022 Sep 11;58(9):1256. doi: 10.3390/medicina58091256.
Total hysterectomy and bilateral adnexectomy is the standard treatment for atypical endometrial hyperplasia and early-stage endometrial cancer. However, the recommended surgical treatment precludes future pregnancy when these conditions are diagnosed in women in their fertile age. In these patients, fertility-sparing treatment may be feasible if the desire for childbearing is consistent and specific conditions are present. This review summarizes the available evidence on fertility-sparing management for atypical endometrial hyperplasia and early-stage endometrial cancer. Historically, oral progestins have been the mainstay of conservative management for atypical endometrial hyperplasia and stage IA endometrioid endometrial cancer with no myometrial invasion, although there is no consensus on dosage and treatment length. Intrauterine progestin therapy has proved a valid alternative option when oral progestins are not tolerated. GnRH analogs, metformin, and hysteroscopic resection in combination with progestins appear to increase the overall efficacy of the treatment. After a complete response, conception is recommended; alternatively, maintenance therapy with strict follow-up has been proposed to decrease recurrence. The risk of disease progression is not negligible, and clinicians should not overlook the risk of hereditary forms of the disease in young patients, in particular, Lynch syndrome. Hysterectomy is performed once the desire for childbearing desire has been established. The conservative management of atypical endometrial hyperplasia and early-stage endometrial cancer is feasible, provided a strong desire for childbearing and permitting clinical-pathological conditions. However, patients must be aware of the need for a strict follow-up and the risk of progression with a possible consequent worsening of the prognosis. More homogenous and well-designed studies are necessary to standardize and identify the best treatment and follow-up protocols.
全子宫切除术和双侧附件切除术是不典型子宫内膜增生和早期子宫内膜癌的标准治疗方法。然而,当这些疾病发生在育龄妇女身上时,推荐的手术治疗会排除未来的妊娠机会。如果有强烈的生育愿望且存在特定条件,对于这些患者,保留生育功能的治疗可能是可行的。本文综述了不典型子宫内膜增生和早期子宫内膜癌的保留生育功能治疗的现有证据。历史上,对于不伴肌层浸润的不典型子宫内膜增生和 I 期子宫内膜样腺癌,口服孕激素一直是保守治疗的主要方法,尽管在剂量和治疗时间方面尚未达成共识。当口服孕激素不能耐受时,宫内孕激素治疗已被证明是一种有效的替代选择。促性腺激素释放激素类似物、二甲双胍和宫腔镜切除联合孕激素似乎增加了治疗的总体效果。完全缓解后,建议妊娠;或者,建议进行维持治疗并严格随访,以降低复发风险。疾病进展的风险不容忽视,临床医生不应忽视年轻患者(尤其是林奇综合征)中遗传性疾病的风险。一旦有生育愿望,就会进行子宫切除术。只要有强烈的生育愿望并符合临床病理条件,保留生育功能治疗不典型子宫内膜增生和早期子宫内膜癌是可行的。然而,患者必须意识到需要严格随访以及疾病进展的风险,这可能导致预后恶化。需要进行更多的同质和精心设计的研究,以标准化并确定最佳的治疗和随访方案。